Cerebral Protection in Transcatheter Left Atrial Appendage Occlusion
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The study aims to assess the effect of the use of neuroprotection in transcutaneous occlusion of the left atrial appendage in patients with atrial fibrillation on the risk of perioperative silent brain ischemia and associated cognitive impairment and depression.
Eligibility Criteria
Inclusion Criteria: 1. 18 Years and older 2. Subject able to provide signed informed consent. 3. Documented permanent, persistent, or paroxysmal atrial fibrillation 4. CHA2DS2VASc risk of stroke ≥2 5. At least one of the following criteria: 1. Contraindications to the use of anticoagulants, 2. HSBLED bleeding risk ≥3 Exclusion Criteria: 1. Serious mental diseases, particularly: dementia syndrome of any etiology, schizophrenia,schizoaffective disorders, bipolar disorder 2. History of ischemic stroke 3. Chronic abuse of alcohol or any other psychoactive substances except for nicotine 4. long-term therapy with benzodiazepines 5. The use of antidepressants in 3 months prior inclusion. 6. Previous infections of the central nervous system, including neuroborreliosis 7. Parkinson's disease 8. Huntington's chorea 9. Creutzfeld-Jakob disease 10. Pick's disease 11. Significant atherosclerosis of the cephalic arteries (\> 70% LCCA or the brachiocephalic trunk) 12. Strictures, ectasias, dissection